- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01583608
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (ASSURE)
ABSORB: Initial Clinical Experience With the Everolimus-eluting Bioresorbable Vascular Scaffold (BVS) System in the Treatment of de Novo Native Coronary Artery Lesions - a Surveillance Registry
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bernau, Germany, 16321
- Herzzentrum Brandenburg in Bernau
-
Coburg, Germany, 96450
- Klinikum Coburg GmbH
-
Essen, Germany, 45138
- Elisabeth-Krankenhaus Essen GmbH
-
Hamburg, Germany, 22527
- Medical Care Center Prof. Mathey, Prof. Schofer GmbH
-
Kiel, Germany, 24105
- Universitätsklinikum Schleswig-Holstein
-
Ulm, Germany, 89081
- Universitatsklinikum Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
The recommendation to implant BVS in an individual patient is purely based on clinical grounds. These are determined by the instructions for use (IFU) of the BVS and by the clinical experience accumulated so far from clinical studies.These studies suggest that the BVS should be implanted under certain conditions, which are determined by the patient and the coronary lesion treated:
Eligible:
Regarding to patient
- Patient ≥ 18 and ≤ 75 years with a live expectancy of at least 5 years with ischemic heart disease (chronic, NSTEMI and unstable angina) due to one or more de novo native coronary artery lesions
- Patients with evidence of myocardial ischemia
Regarding to lesion
- Reference vessel diameter ≥ 2.0 mm and ≤ 3.8 mm, visually estimated and by online QCA
- Percent diameter stenosis ≥ 50% and < 100%, visually estimated and by online QCA
- TIMI ≥1
- Previous interventions of target vessel lesions should have been done ≥ 6 months prior to index procedure and > 10 mm distal to the target lesion
- Previous interventions of non-target vessel lesions should have been done ≥ 30 days prior to index procedure
- In case of >1 target lesions, those should be from different epicardial vessels
Not eligible:
Regarding to patient
- Patient in whom antiplatelet therapy and/or anticoagulant therapy is contraindicated
- Patient with a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, ticlopidine, prasugrel and ticagrelor, everolimus, poly (L-lactide), poly (D,L-lactide), or platinum, or with contrast sensitivity, who cannot be adequately premedicated
- Patient has a known diagnosis of acute myocardial infarction (STEMI) within 72 hours preceding the index procedure and CK and CK-MB have not returned within normal limits at the time of procedure
- Patient is currently experiencing clinical symptoms consistent with STEMI
- Patient has current unstable arrhythmias
- Patient has a known left ventricular ejection fraction < 30%
- Patient has received a heart transplant or any other organ transplant or is waiting for any organ transplant
- Patient receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after procedure
- Patient is receiving immunosuppression therapy and has known immunosuppressive or autoimmune disease
- Patient is receiving or scheduled to receive chronic anticoagulation therapy
- Elective surgery is planned within the first 6 month after the procedure that will require discontinuing either aspirin or clopidogrel
- Patient has a platelet count < 100 000 cells/mm3 or > 700 000 cells/mm3, a WBC of
- < 3000 cells/mm3, or documented or suspected liver disease
- Patient has known renal insufficiency
- Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- Patient has cerebrovascular accident or transient ischemic neurological attack within the past six month
- Patient has had a significant GI or urinary bleed within the past six months
- Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion
- Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non.compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., les than one year)
- Women of childbearing potential who have not undergone surgical sterilization or are not post-menopausal
Regarding to lesion
- Aorto-ostial location
- Left main location
- Located within 2 mm of the origin of LAD or LCX
- Located within an arterial or saphenous vein graft or distal to a diseased (defined as vessel irregularity per angiogram and > 20% stenosed lesion by visual estimation) arterial or saphenous vein graft
- Lesion involving a bifurcation with side branch vessel ≥ 2 mm in diameter, ostial lesion > 40% stenosed by visual estimation or side branch requiring predilation
- Total occlusion (TIMI flow 0), prior to wire passing
- Excessive tortuosity proximal to or within the lesion (extreme angulation (≥ 90°) proximal to or within the lesion)
- Heavy calcification
- Restenotic from previous intervention
- Target vessel is containing thrombus
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
(This trial has no primary outcome, all outcomes are of equal weight), Major Adverse Cardiac Event (MACE)
Time Frame: at 24 months
|
Composite of ischemia driven target lesion revascularisation (TLR), myocardial infarction and cardiac death
|
at 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute procedural success
Time Frame: At the end of hospital stay (maximum of 7 days)
|
Achievement of final in-scaffold residual stenosis of < 50% and TIMI flow 3 of the target site.
Successful delivery and deployment of at least one study scaffold at the intended target lesion and successful withdrawal of the delivery system for all target lesions without occurrence of cardiac death, target vessel MI or repeat TLR during hospital stay (maximum of 7 days).
In dual target lesion setting both lesions must meet clinical procedure success criteria.
|
At the end of hospital stay (maximum of 7 days)
|
Acute device success
Time Frame: At time of intervention
|
Successful delivery and deployment of the first scaffold at the intended target lesion (in overlapping setting both planned scaffolds) and successful withdrawal of delivery system.
Attainment of < 50 % residual stenosis and TIMI flow 3 of the target site, using the BVS without the need for other non- study stents.
|
At time of intervention
|
Scaffold thrombosis
Time Frame: At time of intervention, and at 6, 12, 24, 36 months
|
At time of intervention, and at 6, 12, 24, 36 months
|
|
Cardiac death
Time Frame: At time of intervention, and at 6, 12,24, 36 months
|
At time of intervention, and at 6, 12,24, 36 months
|
|
Myocardial infarction
Time Frame: At time of intervention, and at 6, 12, 24 36 months
|
At time of intervention, and at 6, 12, 24 36 months
|
|
Ischemia driven target lesion revascularisation (TLR)
Time Frame: At time of intervention, and at 6, 12, 24, 36 months
|
Target lesion denominates scaffolded segment and 5 mm beyond.
|
At time of intervention, and at 6, 12, 24, 36 months
|
Major Adverse Cardiac Event (MACE)
Time Frame: At time of intervention, participants will be followed for the duration of hospital stay (an expected average of 3 days), at 6, 12, 36 months
|
Composite of ischemia driven target lesion revascularisation (TLR), myocardial infarction and cardial death
|
At time of intervention, participants will be followed for the duration of hospital stay (an expected average of 3 days), at 6, 12, 36 months
|
Ischemia driven target vessel revascularisation (TVR)
Time Frame: at 6, 12, 24, 36 months
|
TVR is ischemia driven.
|
at 6, 12, 24, 36 months
|
Ischemia driven target vessel failure (TVF)
Time Frame: at 6, 12, 24, 36 month
|
at 6, 12, 24, 36 month
|
|
In-lesion % diameter stenosis
Time Frame: Prior procedure
|
Prior procedure
|
|
In-scaffold % diameter stenosis
Time Frame: At time of intervention and at angiographic FU if applicable
|
At time of intervention and at angiographic FU if applicable
|
|
Minimal lumen diameter (MLD)
Time Frame: Prior and post procedure and at FU if applicable
|
Prior and post procedure and at FU if applicable
|
|
In-scaffold late lumen loss (LLL)
Time Frame: At angiographic follow-up if applicable
|
At angiographic follow-up if applicable
|
|
Proximal and distal late lumen loss (LLL)
Time Frame: At angiographic follow-up if applicable
|
At angiographic follow-up if applicable
|
|
In-lesion late lumen loss
Time Frame: At angiographic follow-up if applicable
|
At angiographic follow-up if applicable
|
|
Response to nitroglycerin
Time Frame: Before scaffold implantation, during angiographic follow-up if applicable
|
Before scaffold implantation, during angiographic follow-up if applicable
|
|
In-lesion angiographic binary restenosis (≥ 50%)
Time Frame: At angiographic follow-up if applicable
|
At angiographic follow-up if applicable
|
|
Curvature (cm-1)
Time Frame: Prior and post procedure and at angiographic follow-up if applicable
|
treated region
|
Prior and post procedure and at angiographic follow-up if applicable
|
Angulation (°)
Time Frame: Prior and post procedure and at angiographic follow-up if applicable
|
Treated region
|
Prior and post procedure and at angiographic follow-up if applicable
|
Clinical success
Time Frame: At time of intervention, and at 6, 12, 24, 36 months
|
Procedural success and freedom from TVF, TVR, CABG and scaffold thrombosis
|
At time of intervention, and at 6, 12, 24, 36 months
|
Coronary artery bypass grafting (CABG)
Time Frame: at 6, 12, 24, 36 month
|
at 6, 12, 24, 36 month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Detlef G Mathey, MD, Medical Care Center Prof. Mathey, Prof. Schofer GmbH
Publications and helpful links
General Publications
- Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011 Oct 4;58(15):1578-88. doi: 10.1016/j.jacc.2011.05.050.
- Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2012 Jan;7(9):1060-1. doi: 10.4244/EIJV7I9A168.
- Diletti R, Onuma Y, Farooq V, Gomez-Lara J, Brugaletta S, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Smits P, Koolen J, Meredith I, Li D, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J Am Coll Cardiol. 2011 Jul 12;58(3):258-64. doi: 10.1016/j.jacc.2011.02.052.
- Gomez-Lara J, Brugaletta S, Farooq V, van Geuns RJ, De Bruyne B, Windecker S, McClean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Morel MA, Dorange C, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc Interv. 2011 Jul;4(7):789-99. doi: 10.1016/j.jcin.2011.04.009.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BVS 12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Foundation IRCCS San Matteo HospitalFondazione Poliambulanza Istituto Ospedaliero; Azienda Ospedaliera Ordine Mauriziano... and other collaboratorsWithdrawnST-elevation Myocardial InfarctionItaly